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Abstract
Background: Left ventricular ejection fraction (LVEF) is among the parameters that are 
usually employed to define surgical timing of severe aortic stenosis (AS). Our hypothesis states 
that even when their LVEF is preserved, patients with severe symptomatic AS have impaired 
myocardial structure and function, and such impairment is related to the deleterious progres-
sion of left ventricular hypertrophy (LVH) from the compensated to the decompensated stage, 
as shown by the changes in diastolic function and the increase in left ventricular end-diastolic 
pressure (LVEDP).
Methods and Results: A total of 26 patients with severe AS and LVEF > 50% referred for 
aortic valve replacement underwent catheterization, echocardiography and an intraoperative 
biopsy. Patients with severe symptomatic AS were classified as: group 1 (G1; compensated LVH, 
LVEDP < 15 mm Hg without coronary artery disease [CAD], n = 7), group 2a (G2a, decom-
pensated LVH, without CAD, n = 7), and group 2b (G2b, decompensated LVH with CAD,  
n = 12). Differences were seen in the following: myocyte area [µm2]: G1: 328 ± 66, G2a:  
376 ± 22, G2b: 385 ± 13, p < 0.01; collagen volume [%]: G1: 4.77 ± 1.27, G2a: 8.40 ± 1.27, 
G2b: 11.05 ± 3.08, p < 0.01; LVEDP normalized by diastolic diameter [mm Hg/mm]: G1: 
0.27 ± 0.01, G2a: 0.39 ± 0.06, G2b: 0.44 ± 0.11, p < 0.02; +dP/dtmax/LVEDP [mm Hg/s/mm Hg]: 
G1: 176 ± 45, G2a: 89.6 ± 20, G2b: 113.1 ± 41, p < 0.01; two-dimensional peak systolic 
longitudinal strain [%]: G1: –17.7 ± 4.75, G2a: –13.4 ± 3.04, G2b: –13.5 ± 3.13, p < 0.05.
Conclusions: Patients with severe symptomatic AS and preserved ejection fraction who de-
velop decompensated LVH characterized by increased LVEDP, exhibit an abnormal myocardial 
structure and diastolic and systolic impairment. (Cardiol J 2015; 22, 6: 613–621)
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Introduction
Management of patients with severe aortic 
stenosis and preserved ejection fraction (EF) is 
still controverted and the decision of whether to 
“watch and see” vs. early intervention remains 
debatable [1–3].
Current guidelines determine surgical timing 
according to symptoms and impairment of systolic 
function, defined by an EF below 50% [4, 5]. Not-
withstanding, some patients operated according 
to that criterion will have a poor outcome in the 
long-term follow-up, demonstrating that in fact, EF 
may not be sensitive enough to be used as a cutoff 
point and prognostic marker [6, 7].
The presence of fibrosis and myocyte changes 
together with an elevation in left ventricular (LV) 
end-diastolic pressure (LVEDP) or systolic func-
tion impairment reduce postoperative survival 
[8–11]. Hence, it could be useful to detect myo-
cardial impairment in order to make therapeutic 
decisions before actual myocardial damage occurs. 
Along these lines, the use of new indices may help 
to identify such changes and define high risk popu-
lations that might benefit from an early surgical 
intervention [12].
Imaging with two-dimensional (2D) strain has 
been shown to be an appropriate method to assess 
myocardial contractility, as well as structure, and 
could be used to detect changes in LV performance 
[13, 14].
We hypothesize that in patients with severe 
symptomatic aortic stenosis (AS), even in the 
presence of a preserved EF, myocardial function 
and structure are impaired, and such impairment 
is related to the progression of LV hypertrophy 
(LVH), from the compensated to the decompen-
sated stage, manifested by an increase in LVEDP.
In this study, we evaluated patients with se-
vere symptomatic AS (SSAS) and preserved EF 
with the purpose of: a) detecting changes in LV 
systolic and diastolic function and their correlation 
with changes in myocardial structure, that could 
allow to discriminate different stages of progres-
sion of LVH, as assessed by LVEDP; b) analyzing 
2D peak systolic longitudinal strain, preoperatively 
and 1 year after the aortic valve replacement, in 
agreement with de preoperative LVEDP values.
Methods
Study population
We prospectively included 26 consecutive pa-
tients (age: 67 ± 11 years, 53% male), with SSAS 
(defined by symptoms such as angina, syncope or 
dyspnea occurring at rest or with exercise) and 
by Doppler echocardiography (valve area < 1 cm2, 
mean gradient > 40 mm Hg) and an EF > 50%, 
referred to the Hospital Universitario Austral 
for aortic valve replacement. Prior to surgery, 
all patients underwent cardiac catheterization 
and Doppler echocardiography, and during valve 
replacement surgery a biopsy was obtained from 
the LV anterolateral wall. At 1 year post valve re-
placement, a new echocardiogram was performed. 
Patients with cardiomyopathy or other concomi-
tant valve diseases were excluded. All patients 
accepted to participate in the study by signing an 
informed consent form (approved according to 
the Ethics Committee guidelines of the Hospi-
tal Universitario Austral) and the Declaration of 
Helsinki (1975). Patients with SSAS were divided 
into three groups according to their LVEDP (< or 
≥ 15 mm Hg) [15] and patients with a LVEDP 
≥ 15 mm Hg were further categorized according 
to the presence of coronary artery disease (CAD) 
(lesion in one coronary artery with obstruction 
≥ 50%): group 1 (G1; compensated LVH, LVEDP 
< 15 mm Hg without CAD, n = 7), group 2a (G2a, 
decompensated LVH without CAD, n = 7), group 
2b (G2b, decompensated LVH with CAD, n = 12).
Study protocol
Echocardiography was performed with as-
sessment of 2D peak systolic global longitudinal 
strain (SGLS) by speckle tracking technique, us-
ing Vingmed VIVID 7 equipment (GE Vingmed, 
Milwaukee, WT, USA) with a 3.5 MHz transducer; 
measurements were performed according to rec-
ommendations of the American Society of Echocar-
diography (ASE) [16]. The following variables were 
calculated: LV fractional shortening, LV volume, EF 
(using Simpson’s method) [16], and midwall frac-
tional shortening (MFS) [17] which was normalized 
by end-systolic meridional stress [18]. Aortic valve 
area was calculated using the continuity equation 
and gradients with the modified Bernoulli equation 
(4V2). Left ventricular mass (LVM) was calculated 
according to the ASE guidelines, and normalized 
by body surface to obtain the LVM index (LVMI); 
values were considered high when they exceeded 
115 g/m2 in men and 95 g/m2 in women [19].
Assessment of 2D peak SGLS (%) of the LV was 
performed with 2D echocardiography and grey scale 
speckle tracking imaging, using 2-, 3-, and 4-cham-
ber views from the apical long axis, and a frame rate 
> 50 frames/s [20]. The Lagrange formula (L2L0/L0) 
was used to calculate percent strain [21]. Strain was 
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quantified using GE software (EchoPAC, version 7.0.0, 
General Electric Vingmed). The endocardial contour 
was traced manually at end-systole; subsequently the 
software automatically traced the region of interest 
concentrically [22]. For strain analysis, each apical 
view was divided into 6 segments and SGLS was 
then calculated from the average of 18 segments.
Catheterization
A LV catheterization was performed prior to 
surgery to record LV pressure and the aortic/LV 
gradient, which were recorded with a computer-
assisted system (Philips XPER (XIM) Xper In-
formation System (XIMs) Polygraph, version 
1.2.0.1474), connected to an Edwards Life Science 
pressure transducer. The following pressures 
were measured: aortic pressure, LV systolic 
pressure [mm Hg] and LVEDP [mm Hg]; the fol-
lowing indices were also calculated: maximal rate 
of rise in LV pressure (+dP/dtmax [mm Hg/s]), the 
inverse slope of the line which results from ap-
plying the Ln to the equation of exponential drop 
in LV pressure during the isovolumic relaxation 
period (linear tau [ms]), and the time elapsed 
since LV pressure drops to 50% of its initial value 
(t50), considering as initial LV pressure the value 
corresponding to –dP/dtmax.
The contractility index was calculated as the 
ratio between maximal rate of rise in LV pressure 
(+dP/dtmax [mm Hg/s]) normalized by LVEDP [23].
The two components of diastolic function were 
evaluated: myocardial relaxation and myocardial 
chamber stiffness. To evaluate myocardial cham-
ber stiffness we calculated the ratio between LV 
pressure and LV end-diastolic diameter. In order 
to assess the catheter sensitivity, the recording of 
ventricular pressure of the conventional catheter 
was compared in 3 patients with that obtained 
by a catheter tip transducer (Millar Instruments 
Inc.) that prevents potential problems caused by 
the fluid filled catheter. We observed that both the 
rise and decay slopes of the ventricular pressure 
were similar, therefore no differences were found 
in the measurements of the relaxation variables. 
As expected, measurements of the systolic and di-
astolic pressures were similar with both catheters.
Histomorphometric analysis
Myocardial biopsies of the LV free wall were 
obtained during aortic valve replacement proce-
dures. Tissue samples were fixed in 10% buff-
ered formalin at room temperature and paraffin-
embedded; subsequently, 5 μm serial sections 
were obtained and stained with hematoxylin and 
eosin, Picrosirius red and rhodamine-conjugated 
lectin (WGA# RL-1022, Vector Laboratories, 
Burlingame, CA).
Myocyte cross-sectional area was determined 
on digitized images of rhodamine-conjugated 
lectin-staining; such images were obtained using 
a fluorescence microscope (Olympus BX61) at-
tached to a digital camera and connected to a com-
puter equipped with image analysis software. Myo-
cytes’ outlines were traced and cell areas measured 
with Image-Pro Plus 6.0 (Media Cybernetics, Inc., 
Silver Spring, Md). At least 80 measurable cross 
sections of myocytes were routinely measured 
[24]. In the slices stained with Picrosirius red, 
interstitial collagen deposition was also measured 
using the image analysis system described above. 
Percent collagen volume for each region was calcu-
lated by adding the collagen areas and dividing that 
number by the sum of myocyte areas plus collagen 
areas, as previously described [24].
Statistical analysis
Parameter reproducibility was analyzed twice 
by the same observer (intraobserver variability) 
and by 2 independent operators in 8 patients (inter-
observer variability); variability coefficients were 
5.4% and 6.2%, respectively.
Qualitative variables were expressed as ab-
solute values, proportions and/or percentages, 
with their 95% confidence intervals (CI). Con-
tinuous variables were expressed as means and 
standard deviations, after accepting their normal 
distribution with D’Agostino-Pearson’s test; when 
variables were not distributed normally, they were 
expressed as medians and inter-quartile ranges. 
Comparison among discrete variables was per-
formed with Pearson’s c2 test, among continuous 
variables with the unpaired Student’s t test for 
normal distributions and equal variances and for 
non-normal distributions with Mann-Whitney’s 
U test. Association among continuous variables 
was determined with linear and nonlinear regres-
sion. To compare two or more independent groups, 
the one-way ANOVA test was used, with a post-hoc 
Tukey test to assess group differences. Tests were 
two-tailed and a p value < 0.05 was considered 
statistically significant.
Results
The clinical characteristics of patients in the 
three groups (n = 26) are depicted in Table 1.
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Cardiac structure and function
Endomyocardial biopsy. Differences among 
groups were seen in myocardial structure ex-
pressed by myocyte area (p < 0.01) as well as by 
collagen volume (p < 0.01) (Table 1). The LVMI 
was similar in all groups; however, morphometric 
analysis showed that in group 1 myocyte area and 
collagen volume were smaller than in groups with 
decompensated LVH (Figs. 1A, B).
Patients in G1 exhibited a proportional in-
crease in collagen volume for a certain increase in 
in myocyte area; such relation was lost in patients 
with decompensated LVH, in whom for a certain 
increase in myocyte area there was a dispropor-
tionate rise in collagen volume; this phenomenon 
reached its maximum expression in patients with 
CAD (Fig. 2).
Diastolic function. In the absence of changes 
in diastolic diameters, the difference in LVEDP 
between the three groups attests to an increase 
in myocardial stiffness in the groups with decom-
pensated LVH (Fig. 3).
All patients had impairment in myocardial 
relaxation, expressed by a change in tau and tau50, 
and without differences among groups (Table 1). 
The rise in LVEDP correlated directly with the 
changes in structure assessed by collagen volume 
(regression coefficient 0.97, p < 0.001) (Fig. 4). 
Table 1. Clinical, hemodynamic and echocardiographic variables in basal condition.
Group 1 Group 2a Group 2b P
Clinical variables
Age 68 ± 12 64.14 ± 9.92 71 ± 11.59 NS
Gender: male/female 2/5 3/4 9/3
Systolic blood pressure [mm Hg] 119.71 ± 22.84 125.14 ± 5.87 132 ± 9.03 NS
NYHA functional class for angina:
II 3 3 1
III 1 2
IV 1
NYHA functional class for dyspnea:
II 3 6 4
III 3 3
IV
Syncope 0 1 1 NS
Cardiac catheterization
LVESP [mm Hg] 202.5 ± 19.46 211.28 ± 40.47 193.16 ± 24.37 NS
+dP/dtmax [mm Hg/s] 2,230.75 ± 493.03 1,830.28±346.98 2,231.55 ± 313.02 0.07
tau50 24.99 ± 2.41 32.66 ± 5.96 32.52 ± 8.85 NS
Echocardiography
Ejection fraction [%] 75.71 ± 5.93 64 ± 6.03 66.72  ± 10.65 0.04
End-systolic diameter [mm] 29.74 ± 6.26 26.33 ± 5.39 33.37 ± 8.06 NS
End-diastolic diameter [mm] 49.31 ± 5.29 48.16 ± 5.15 52.75 ± 4.15 NS
Myocardial mass index [g/m2] 198 ± 85 162 ± 43 209 ± 42 NS
End-systolic meridional stress 
[kdynes/cm2]
42.54 ± 22.03 37.7 ± 14.98 51.67 ± 24.15 NS
Midwall fractional shortening [%] 14.15 ± 3.95 14.96 ± 2.7 13.48 ± 4.35 NS
Midwall fractional shortening/stress 18.68 ± 0.83 18.86 ± 0.56 18.05 ± 1.04 NS
Aortic valve area [cm2] 0.77 ± 0.26 0.45 ± 0.07 0.74 ± 0.15 NS
Mean aortic gradient [mm Hg] 52.74 ± 18.87 66.83 ± 10.83 48.36 ± 9.42 < 0.05
Peak aortic gradient [mm Hg] 89.28 ± 26.32 103.66 ± 15.06 80.09 ± 16.1 0.07
1 — compensated hypertrophy; 2a — decompensated hypertrophy without coronary artery disease; 2b — decompensated hypertrophy with 
coronary artery disease; LVESP — left ventricular end-systolic pressure; NS — not significant; NYHA — New York Heart Association 
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A positive correlation, r = 0.53, p = 0.04, was also 
seen between LVEDP and SGLS.
Systolic function. The LVEF was within nor-
mal limits in all patient groups, and there were no 
differences in LVMI, MFS at baseline and normal-
ized by wall stress or LVESP measured by cardiac 
catheterization (Table 1). However, differences 
were seen in a preload-adjusted systolic function 
index (+dP/dtmáx [mm Hg/s] normalized by LVEDP 
[mm Hg]) and in SGLS, thus, impairment of sys-
tolic function was more marked in patients with 
decompensated hypertrophy (Figs. 5, 6).
A positive correlation, r = 0.71, p = 0.007, 
was found between the hemodynamic index of 
contractile status (+dP/dtmáx [mm Hg/s] normalized 
by LVEDP [mm Hg]) and SGLS.
Discussion
This study shows that in patients with se-
vere AS and preserved LV function, the adaptive 
mechanism of hypertrophy exhibits various stages 
of progression, expressed by changes in LV func-
tion and structure, which allow to identify groups 
of patients with different degrees of myocardial 
Figure 1. A. Differences in myocyte cross sectional area between groups; B. Differences in collagen volume expressed 
as percent between groups; *p < 0.05 G1 vs. G2a and G2b.
Figure 2. Quadratic function expressing the relation 
between collagen volume and the myocyte area in the 
various groups (R2 = 0.73).
Figure 3. Graphic depicting differences in myocardial 
stiffness between groups; LVEDP — left ventricular end-
diastolic pressure; LVDD — left ventricular diastolic di-
ameter.
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impairment. Early identification of such a myocar-
dial impairment is important for decision making in 
valve disease in general, and particularly in AS. In 
the cases of increased wall stress, the myocardium 
develops ventricular hypertrophy as a compensatory 
response; such hypertrophy presents as quantita-
tive and qualitative changes, increase in mass and 
changes in structure. In the present study, we con-
sidered the increase in collagen volume a qualitative 
change which occurred without differences in LVMI 
between groups. As Weber [25] stated: “It is not 
the quantity but rather the quality of myocardium 
that distinguishes hypertensive heart disease from 
adaptive hypertrophy of the athlete”.
Decompensated groups exhibit greater im-
pairment in structure characterized by a larger 
myocyte area and greater increase in collagen, 
with marked increase in myocardial stiffness. This 
impairment in diastolic function and its correlation 
with changes in structure was described in previ-
ous studies [10, 11], albeit in patients with less 
preserved EF than patients in our population, and 
without changes that allow to discriminate different 
groups with different stages of disease progression.
Although the increase in collagen volume of 
the compensated group is twofold the reference 
values for a normal population [26], it is much less 
than that found in the decompensated group. In-
crease in collagen is probably due to impairment in 
myocardial perfusion, secondary to the loss of coro-
nary vasodilatory reserve and elevated wall stress, 
resulting in a predominant increase in subendo-
cardial fibrosis as the disease progresses [27, 28]. 
Figure 6. Left ventricular peak systolic global longitu-
dinal 2-dimensional strain (SGLS) at 1 year post aortic 
valve replacement, expressed as percent, for groups 
G1, G2a and G2b (*p < 0.05 G1 vs. G2a and G2b).
Figure 4. Linear regression of the relation between left 
ventricular end-diastolic pressure (LVEDP) in mm Hg and 
collagen volume in percent (correlation coefficient = 0.96, 
p < 0.001).
Figure 5. A. Analysis of +dP/dtmax (mm Hg/s) normal-
ized by left ventricular end-diastolic pressure (LVEDP), 
for the three groups. (*p < 0.05 G1 vs. G2a and G2b); 
B. Left ventricular peak systolic global longitudinal 
2-dimensional strain (SGLS), expressed as percent, for 
the three groups (*p < 0.05 G1 vs. G2a and G2b).
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A special condition is that of patients with con-
comitant CAD, in whom this mechanism adds on 
to those previously described.
All groups had impaired myocardial relaxation, 
as assessed by tau50; these changes seen in AS have 
been previously described in animal models [29], 
as well as in clinical studies [30], and are related 
(among other processes) to intracellular movement 
of calcium, thus it could be part of the mechanisms 
resulting in progressive failure of the hypertrophic 
myocardium [31].
Impairment of diastolic function in AS has been 
described as a prognostic factor, pre- and postop-
eratively, and some authors have suggested that 
its finding should be considered for early surgical 
intervention [32].
All patients in our study had a normal EF, 
a parameter that is used to express absence of fail-
ure of the global LV function; however, this index is 
subject to variations depending on the chamber’s 
geometry, afterload and increase in mass [33–35], 
among other variables. Hence, EF is more pre-
cise to evaluate pump function than ventricular 
function, since it mainly expresses the radial 
function of the myocardium and is less affected 
by abnormalities of the subendocardium [36]. 
A more specific index of the assessment of func-
tion in the presence of hypertrophy, MFS [37], 
was normal in all group after normalizing by wall 
stress, probably because it was evaluated in pa-
tients with normal EF and an end-systolic stress 
which did not exceed 120 kdynes/cm2 (according 
to several studies, LVH should be considered in-
appropriate when values exceed this cutoff level) 
[18]; this could explain the failure of this index 
in detecting contractile function impairment in 
this study.
More sensitive parameters useful to assess 
contractile status are: +dP/dtmax [38] normalized 
by LVEDP, and SGLS, which allows to assess 
contractile properties of the myocardium [39] in 
various scenarios including AS [13], confirmed 
the impairment of systolic function, especially in 
decompensated groups, and could thus be useful 
tools to characterize subtle changes in ventricular 
function. Interestingly, a significant positive cor-
relation was observed between both parameters 
assessing LV contractile status.
This myocardial impairment and structural 
changes initially and mainly involve the subendo-
cardium [40], affecting longitudinal function, which 
is not well assessed by EF, but can be assessed by 
other indices that use M-mode and/or tissue Dop-
pler imaging to analyze the lateral displacement of 
the mitral annulus [41].
Various authors have observed the association 
between strain impairment in patients with SSAS 
and its impact on increased risk and clinical events 
in the long-term follow-up [42].
Lancellotti et al. [43] studied patients with 
asymptomatic AS and saw that a SGLS < 15.9% 
was a prognostic marker of an adverse course. In 
our patients, the compensated group exhibited 
values above the cutoff point, whereas in the de-
compensated group with and without CAD, values 
were 13.5% and 13.6%, respectively. Other authors 
demonstrated that SGLS returned to normal val-
ues at 1 year post valve replacement [44]; in our 
study SGLS values returned to normal only in the 
compensated group (Table 2).
Correlation between the degree of fibrosis 
and changes in strain has been described by other 
authors [45] and by our group [14], as well as the 
improvement and/or normalization of strain values 
after aortic valve replacement [46]; however, we 
are not aware of any publication showing that in 
patients with preserved EF and MFS at baseline, 
two groups of patients could be distinguished by 
structure, function, baseline systo-diastolic func-
tion and a different strain pattern at 1 year. Evi-
Table 2. One-year echocardiography data.
Echocardiography at 1 year Group 1 Group 2a Group 2b P
Ejection fraction [%] 62.75 ± 13.81 55 65 ± 5.83 NS
End-systolic diameter [mm] 27.5 ± 2.38 37 30.75 ± 4.27 NS
End-diastolic diameter [mm] 48.25 ± 2.87 61 48.75 ± 3.77 NS
Myocardial mass index [g/m2] 136.2 ± 54.97 158.66 ± 24.36 159.18 ± 35.45 NS
Midwall fractional shortening [%] 17.63 ± 1.42 16.24 ± 2.51 14.62 ± 1.35 0.01
Midwall fractional shortening/stress 18.09 ± 0.49 18.29 ± 0.22 18.47 ± 0.58 NS
1 — compensated hypertrophy; 2a — decompensated hypertrophy without coronary artery disease; 2b — decompensated hypertrophy with 
coronary artery disease; NS — not significant
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dence shows that changes in structure, particularly 
fibrosis, are an early finding in the progression of 
AS [47] and determine aspects of systolic, as well 
as diastolic function [48], which entail prognostic 
value and affect long-term survival following aortic 
valve replacement [49]. This adverse progression 
is related to myocardial failure which is probably 
an evolving process, as described by Meerson [50], 
and of which many aspects remain unknown. Early 
detection of myocardial impairment is clinically 
important, and detecting the various stages of 
progression of hypertrophy can be very useful for 
decision making.
The present study contributes information 
about the changes in cardiac structure and func-
tion in AS that may be useful for clinical manage-
ment, and suggest a transition in the progression 
of ventricular hypertrophy to myocardial failure. 
Some of these changes remain abnormal at 1 year 
after valve replacement in the group of patients 
with decompensated hypertrophy.
Limitations of the study
Our results should be validated in a larger 
number of patients. The information found is only 
applicable to a symptomatic patient population. 
One-year follow-up does not provide information 
about the clinical course and LV function changes 
in the mid- and long-term follow-up.
Conclusions
Patients with SSAS and preserved EF who 
progress to decompensated LVH characterized 
by an increase in LVEDP, exhibit impairment in 
their myocardial structure and diastolic function 
expressed by changes in ventricular relaxation and 
myocardial stiffness, as well as in their systolic 
function expressed by hemodynamic and myocar-
dial strain indices.
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